MAR CARRION CABALLO

Dr. MAR CARRION CABALLO

Departamento de Biología Celular,Universidad Complutense de Madrid,28040 Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MCMAR CARRION CABALLO
MAR CARRION CABALLO
Frommer KlausFrommer Klaus
Frommer Klaus
SGSelene Pérez García
Selene Pérez García
UMUlf Müller-Ladner
Ulf Müller-Ladner
RGRosa P. Gomariz
Rosa P. Gomariz
ENElena Neumann
Elena Neumann
Rheumatic diseases encompass a diverse group of chronic disorders that commonly affect musculoskeletal structures. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most common, leading to considerable functional limitations and irreversible disability when patients are unsuccessfully treated. Although the specific causes of many rheumatic conditions remain unknown, it is generally accepted that immune mechanisms and/or uncontrolled inflammatory responses are involved in their etiology and symptomatology. In this regard, the bidirectional communication between neuroendocrine and immune system has been demonstrated to provide a homeostatic network that is involved in several pathological conditions. Adipokines represent a wide variety of bioactive, immune and inflammatory mediators mainly released by adipocytes that act as signal molecules in the neuroendocrine-immune interactions. Adipokines can also be synthesized by synoviocytes, osteoclasts, osteoblasts, chondrocytes and inflammatory cells in the joint microenvironment, showing potent modulatory properties on different effector cells in OA and RA pathogenesis. Effects of adiponectin, leptin, resistin and visfatin on local and systemic inflammation are broadly described. However, more recently, other adipokines, such as progranulin, chemerin, lipocalin-2, vaspin, omentin-1 and nesfatin, have been recognized to display immunomodulatory actions in rheumatic diseases. This review highlights the latest relevant findings on the role of the adipokine network in the pathophysiology of OA and RA.

22 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
SGSelene Pérez García
Selene Pérez García
MCMAR CARRION CABALLO
MAR CARRION CABALLO
Irene Gutiérrez-CañasIrene Gutiérrez-Cañas
Irene Gutiérrez-Cañas
RRRaúl Villanueva Romero
Raúl Villanueva Romero
DCDavid Castro-Vazquez
David Castro-Vazquez
RGRosa P. Gomariz
Rosa P. Gomariz
The extracellular matrix (ECM) is a complex and specialized three-dimensional macromolecular network, present in nearly all tissues, that also interacts with cell surface receptors on joint resident cells. Changes in the composition and physical properties of the ECM lead to the development of many diseases, including osteoarthritis (OA). OA is a chronic degenerative rheumatic disease characterized by a progressive loss of synovial joint function as a consequence of the degradation of articular cartilage, also associated with alterations in the synovial membrane and subchondral bone. During OA, ECM-degrading enzymes, including urokinase-type plasminogen activator (uPA), matrix metalloproteinases (MMPs), and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs), cleave ECM components, such as fibronectin (Fn), generating fibronectin fragments (Fn-fs) with catabolic properties. In turn, Fn-fs promote activation of these proteinases, establishing a degradative and inflammatory feedback loop. Thus, the aim of this review is to update the contribution of ECM-degrading proteinases to the physiopathology of OA as well as their modulation by Fn-fs.

19 September 2013 in Rheumatology
Verified
Journal Article
Open access
PDF file
MCMAR CARRION CABALLO
MAR CARRION CABALLO
Yasmina JuarranzYasmina Juarranz
Yasmina Juarranz
CMCarmen Martínez
Carmen Martínez
IGIsidoro González-Álvaro
Isidoro González-Álvaro
JPJosé L. Pablos
José L. Pablos
RGRosa P. Gomariz
Rosa P. Gomariz
Objectives. Fibroblast-like synoviocytes (FLSs) are crucial players in the pathogenesis of synovitis in rheumatic diseases. Targeting FLS activation represents an approach to the development of therapeutic strategies. Our aim was to investigate whether the microenvironment of inflamed joints could modulate the expression of IL-22 and IL-22R1 on OA and RA FLSs. We also examined the effect of IL-22 on FLS activation as well as on their IL-17-related responses. Methods. IL-22 and IL-22R1 expression was studied by RT-PCR and immunoblotting. Proliferation was measured by an ELISA kit. IL-17 receptors, p19IL-23 and alarmins were analysed by RT-PCR. IL-17 receptor expression was evaluated by flow cytometry. MMP1 and IL-23 were measured by ELISA. S100A8/A9 expression was detected by immunofluorescence and ELISA. Signal transducer and activator of transcription 3 (STAT3) phosphorylation was quantified using a cell-based ELISA kit. Results. IL-22 and IL-22R1 were expressed constitutively in FLSs. We demonstrated that S100A8 and S100A9 were synthesized in FLSs. We reported that inflammatory mediators increased the expression of the IL-22/IL-22R1 axis, amplifying FLS activation. IL-22 enhanced FLS proliferation and up-regulated MMP1 and S100A8/A9 production. STAT3 phosphorylation was induced after IL-22 treatment and the stimulatory effect of IL-22 on S100A8/A9 was reduced after the activities of Janus kinase 2 (JAK2) and JAK3 were blocked. We showed an inhibitory action of IL-22 on IL-23 and IL-17RC expression in RA FLSs and on IL-17RA in OA FLSs. Conclusion. Therapies based on the pharmacological disruption signalling of IL-22 could be beneficial for the treatment of rheumatic diseases. The restricted expression of IL-22R1 to non-lymphoid cells could lead to a reduction of side effects mediated by immune responses.

27 March 2008 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
Yasmina JuarranzYasmina Juarranz
Yasmina Juarranz
Irene Gutiérrez-CañasIrene Gutiérrez-Cañas
Irene Gutiérrez-Cañas
BSBegoña Santiago
Begoña Santiago
MCMAR CARRION CABALLO
MAR CARRION CABALLO
JPJosé L. Pablos
José L. Pablos
RGRosa P. Gomariz
Rosa P. Gomariz
Objective: Vasoactive intestinal peptide (VIP) has shown potent antiinflammatory effects in murine arthritis and ex vivo in human rheumatoid arthritis (RA) synovial cells. To investigate the potential endogenous participation of this system in the pathogenesis of RA, we analyzed the expression and regulation of VIP and its functional receptors in human fibroblast‐like synoviocytes (FLS) from patients with osteoarthritis (OA) and patients with RA.Methods: The expression of VIP was studied by reverse transcription–polymerase chain reaction (RT‐PCR), enzyme immunoassay, and immunofluorescence in cultured FLS, and by immunohistochemical analysis in synovial tissue. The expression and function of the potential VIP receptors in FLS were studied by RT‐PCR, determination of intracellular cAMP production, cell membrane adenylate cyclase (AC) activity, and interleukin‐6, CCL2, and CXCL8 production in response to VIP or specific agonists and antagonists.Results: VIP expression was detected in human FLS at the messenger RNA and protein levels, and it was significantly decreased in RA FLS compared with OA FLS. VIP receptor type 1 (VPAC1) was the dominant AC‐coupled receptor in OA FLS, in contrast with RA FLS, in which VPAC2 was dominant. Tumor necrosis factor α–treated OA FLS reproduced the VIP and VPAC receptor expression pattern of RA FLS. The antagonistic effects of VIP on FLS proinflammatory factor production were reproduced by VPAC1‐ and VPAC2‐specific agonists in OA FLS and RA FLS, respectively.Conclusion: VIP expression is down‐regulated in RA and in tumor necrosis factor α–treated FLS, suggesting that down‐regulation of this endogenous antiinflammatory factor may contribute to the pathogenesis of RA. In RA FLS, VPAC2 mediates the antiinflammatory effects of VIP, suggesting that VPAC2 agonists may be an alternative to VIP as antiinflammatory agents.

17 February 2011 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MCMAR CARRION CABALLO
MAR CARRION CABALLO
Yasmina JuarranzYasmina Juarranz
Yasmina Juarranz
SGSelene Pérez García
Selene Pérez García
RJRebeca Jimeno
Rebeca Jimeno
JPJosé L. Pablos
José L. Pablos
Irene Gutiérrez-CañasIrene Gutiérrez-Cañas
Irene Gutiérrez-Cañas
Objective The aim of this study was to analyze both the constitutive and induced expression and function of double‐stranded RNA (dsRNA; Toll‐like receptor 3 [TLR‐3], retinoic acid–inducible gene I [RIG‐I], and melanoma differentiation‐associated gene 5 [MDA5]) and single‐stranded RNA (ssRNA; TLR‐7) receptors in osteoarthritis (OA) and rheumatoid arthritis (RA) fibroblast‐like synoviocytes (FLS), by studying the transcription factors involved and the subsequent effects on antiviral interferon‐β (IFNβ), the proinflammatory CXCL8 chemokine, and matrix metalloproteinase 3 (MMP‐3). An additional goal was to study the effect of vasoactive intestinal peptide (VIP). Methods The expression of TLR‐3, TLR‐7, RIG‐I, and MDA5 in cultured FLS was studied by reverse transcription–polymerase chain reaction (RT‐PCR), enzyme‐linked immunosorbent assay (ELISA), immunofluorescence, and Western blotting. Transcription factors were studied using the ELISA‐based TransAM transcription factor kit. The expression of IFNβ, CXCL8 (interleukin‐8), and MMP‐3 was analyzed by RT‐PCR and ELISA. Results FLS expressed TLR‐3, TLR‐7, RIG‐I, and MDA5. The expression of TLR‐3 and RIG‐I was higher in RA FLS, while the expression of TLR‐7 and MDA5 was higher in OA FLS. Stimulation with poly(I‐C) induced the activation of IFN regulatory factor 3 (IRF‐3), NF‐κB, and activator protein 1 (AP‐1) c‐Jun as well as the subsequent production of IFNβ, CXCL8, and MMP‐3. VIP reduced the activation of IRF‐3 and the production of IFNβ in both OA and RA FLS. Imiquimod induced the activation of NF‐κB, AP‐1 c‐Fos, and AP‐1 c‐Jun and the synthesis of CXCL8 and MMP‐3. VIP significantly diminished MMP‐3 production only in imiquimod‐treated RA FLS. Conclusion The results of this study revealed a prominent function of FLS in the recognition of both dsRNA and ssRNA, which may be present in the joint microenvironment. This study also advances the healing function of the endogenous neuroimmune peptide VIP, which inhibited TLR‐3–, RIG‐I–, MDA5‐, and TLR‐7–mediated stimulation of antiviral, proinflammatory, and joint destruction mediators.

Verified
Journal Article
Open access
PDF file
CMCarmen Martínez
Carmen Martínez
Yasmina JuarranzYasmina Juarranz
Yasmina Juarranz
Irene Gutiérrez-CañasIrene Gutiérrez-Cañas
Irene Gutiérrez-Cañas
MCMAR CARRION CABALLO
MAR CARRION CABALLO
SGSelene Pérez García
Selene Pérez García
RGRosa P. Gomariz
Rosa P. Gomariz
The neuroendocrine and immune systems are coordinated to maintain the homeostasis of the organism, generating bidirectional communication through shared mediators and receptors. Vasoactive intestinal peptide (VIP) is the paradigm of an endogenous neuropeptide produced by neurons and endocrine and immune cells, involved in the control of both innate and adaptive immune responses. Exogenous administration of VIP exerts therapeutic effects in models of autoimmune/inflammatory diseases mediated by G-protein-coupled receptors (VPAC1 and VPAC2). Currently, there are no curative therapies for inflammatory and autoimmune diseases, and patients present complex diagnostic, therapeutic, and prognostic problems in daily clinical practice due to their heterogeneous nature. This review focuses on the biology of VIP and VIP receptor signaling, as well as its protective effects as an immunomodulatory factor. Recent progress in improving the stability, selectivity, and effectiveness of VIP/receptors analogues and new routes of administration are highlighted, as well as important advances in their use as biomarkers, contributing to their potential application in precision medicine. On the 50th anniversary of VIP’s discovery, this review presents a spectrum of potential clinical benefits applied to inflammatory and autoimmune diseases.